Related Experiment Videos

Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype

E Berman1, M Adams, R Duigou-Osterndorf

  • 1Laboratory of Hematopoietic Cell Kinetics, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.

Blood
|February 15, 1991
PubMed

Insights

Tamoxifen (Tmx) increases intracellular daunorubicin (DNR) uptake and retention in multidrug-resistant (MDR) cancer cells. Tmx enhances DNR

Area of Science:

  • Pharmacology
  • Cancer Biology
  • Drug Resistance

Background:

  • Multidrug resistance (MDR) is a major challenge in cancer chemotherapy.
  • Tamoxifen (Tmx) and verapamil are known modulators of drug efflux pumps.
  • Daunorubicin (DNR) is an anthracycline chemotherapy drug.

Purpose of the Study:

  • To investigate the effect of tamoxifen (Tmx) and verapamil on intracellular daunorubicin (DNR) content in multidrug-resistant (MDR) cell lines.
  • To evaluate the impact of Tmx on DNR cytotoxicity and cellular retention in MDR cells.
  • To determine if Tmx potentiates DNR's anti-cancer effects.

Main Methods:

  • Utilized laser flow cytometry to quantify intracellular DNR fluorescence in MDR cell lines (CEM-VBL and HL-60/RV+).
  • Assessed cellular retention of DNR with continuous Tmx exposure.
  • Performed clonogenic assays to evaluate Tmx's inherent cytotoxicity and its potentiation of DNR cytotoxicity.

Main Results:

  • Tmx significantly increased intracellular DNR uptake and retention in a dose-dependent manner in MDR cell lines, similar to verapamil.
  • Continuous Tmx exposure led to higher intracellular DNR levels compared to fresh medium.
  • Tmx alone at 10 µmol/L showed minimal inhibition, but potentiated DNR cytotoxicity significantly.

Conclusions:

  • Tamoxifen effectively enhances intracellular daunorubicin accumulation in multidrug-resistant cancer cells.
  • Tamoxifen potentiates the cytotoxic effects of daunorubicin, suggesting a potential therapeutic synergy.
  • Clinical investigation of tamoxifen and daunorubicin combination therapy is warranted for MDR cancers.

Related Concept Videos